Lead asset aleniglipron: oral small-molecule GLP-1 agonist. Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted weight loss at 36 weeks. Roche licensing deal ($100M) for additional assets signals strategic interest.
Lead asset aleniglipron: oral small-molecule GLP-1 agonist. Two positive Phase 2 readouts; high-dose 11%+ placebo-adjusted weight loss at 36 weeks. Roche licensing deal ($100M) for additional assets signals strategic interest.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling: